

WP4/HARMONY PLUS Session
March 9, 2021, 11:30 – 13:00



Chairs: F. Guilhot, A. Hochhaus, L. Stenke

Welcome		5'
New data from the Swedish CML registry	<i>Torsten Dahlen (Stockholm, Sweden)</i>	10'+5'
HARMONY PLUS: Introduction	<i>Andreas Hochhaus (Jena, Germany)</i>	5'
HARMONY PLUS: Clonal hierarchy in CML	<i>Thomas Ernst (Jena, Germany)</i>	10'+5'
CML and COVID-19: Mutual impact of the two diseases.	<i>Delphine Rea (Paris, France)</i>	10'+5'
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for CML: results from the French SPIRIT phase III trial.	<i>Francois Guilhot (Poitiers, France)</i>	10'+5'
Interim results of a study of de-escalation TKI doses in CML patients. Study of the plasma concentration of TKI in CML patients on therapy with various doses of TKI.	<i>Margarita Gurianova (Moscow, Russia)</i>	10'+5'
Conclusion		5'